Cetrorelix vs Lutropin alfa

Head-to-head comparison of Cetrorelix (Cetrorelix acetate) and Lutropin alfa (Recombinant Human Luteinizing Hormone Alfa) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyCetrorelixLutropin alfa
CategorySexual HealthSexual Health
Full NameCetrorelix acetateRecombinant Human Luteinizing Hormone Alfa
Molecular Weight1431.06 Da30,000 Da
Half-Life~30 hours~10-12 hours
Amino Acids10N/A
Typical Dose0.25 mg SC daily75-150 IU per dose
RouteSubcutaneousSubcutaneous/Intramuscular
Purity≥98%≥98%
Studies Count300420
Research StatusClinicalClinical

Cetrorelix Benefits

  • prevents premature ovulation
  • supports IVF cycle control
  • blocks LH surge
  • short-acting pituitary suppression

Lutropin alfa Benefits

  • stimulates Leydig cells
  • raises endogenous testosterone
  • supports testicular steroidogenesis
  • pairs with FSH for fertility

Cetrorelix Dosing

0.25 mg SC daily|start on stimulation day 5-6|protocol-dependent antagonist cycle

Lutropin alfa Dosing

75-150 IU SC/IM 2-3x weekly|adjust to testosterone response|combine with FSH when spermatogenesis support is needed

Cetrorelix Side Effects

  • injection-site reactions
  • headache
  • nausea

Lutropin alfa Side Effects

  • injection-site reactions
  • headache
  • hormonal swings

Research Overview

Cetrorelix

Cetrorelix is a cornerstone GnRH antagonist in assisted reproduction, with a fast onset and reversible suppression of LH. Trials show it improves cycle management by reducing premature ovulation during stimulation.

Lutropin alfa

Lutropin alfa has been evaluated in fertility protocols to restore LH signaling and endogenous testosterone production. It is a direct research/clinical analogue for men with low gonadotropin drive.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Cetrorelix stacks with:

FSHhCG

Lutropin alfa stacks with:

Follitropin alfahCG
GnRH-antagonistfertilityivfLHtestosteroneclinical